|
1
|
Xin Yu J, Hubbard-Lucey VM and Tang J:
Immuno-oncology drug development goes global. Nat Rev Drug Discov.
18:899–900. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sanmamed MF and Chen L: A paradigm shift
in cancer immunotherapy: From enhancement to normalization. Cell.
175:313–326. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xin Yu J, Hubbard-Lucey VM and Tang J: The
global pipeline of cell therapies for cancer. Nat Rev Drug Discov.
18:821–822. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yagi Y, Kanemasa Y, Sasaki Y, Goto S,
Yamamura Y, Masuda Y, Fujita K, Ishimine K, Hayashi Y, Mino M, et
al: Early failure is still a poor prognostic factor in patients
with relapsed or refractory large B-cell lymphoma in the era of CAR
T-cell therapy. J Clin Exp Hematop. 64:107–118. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shumilov E, Scholz JK, Seib M, Mazzeo P,
Wurm-Kuczera R, Vucinic V, Holtick U, Boyadzhiev H, Melchardt T,
Hölscher AS, et al: Outcomes of bispecific antibody therapy after
CAR T-cell failure in relapsed/refractory large B-cell lymphoma.
Blood Adv. 9:3955–3966. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Manfredi F, Cianciotti BC, Potenza A,
Tassi E, Noviello M, Biondi A, Ciceri F, Bonini C and Ruggiero E:
TCR redirected T cells for cancer treatment: Achievements, hurdles,
and goals. Front Immunol. 11:16892020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Drewniak-Świtalska M, Fortuna P and
Krzystek-Korpacka M: Negative immune checkpoint inhibitors.
Pharmaceutics. 17:7132025. View Article : Google Scholar :
|
|
8
|
Safarzadeh Kozani P, Naseri A, Mirarefin
SMJ, Salem F, Nikbakht M, Evazi Bakhshi S and Safarzadeh Kozani P:
Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res.
10:242022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun W, Xie J, Lin H, Mi S, Li Z, Hua F and
Hu Z: A combined strategy improves the solubility of
aggregation-prone single-chain variable fragment antibodies.
Protein Expr Purif. 83:21–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Aguiar RB, da Silva TA, Costa BA,
Machado MFM, Yamada RY, Braggion C, Perez KR, Mori MAS, Oliveira V
and de Moraes JZ: Generation and functional characterization of a
single-chain variable fragment (scFv) of the anti-FGF2 3F12E7
monoclonal antibody. Sci Rep. 11:14322021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koch-Nolte F: Nanobody-based heavy chain
antibodies and chimeric antibodies. Immunol Rev. 328:466–472. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ingram JR, Schmidt FI and Ploegh HL:
Exploiting nanobodies' singular traits. Annu Rev Immunol.
36:695–715. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
De Meyer T, Muyldermans S and Depicker A:
Nanobody-based products as research and diagnostic tools. Trends
Biotechnol. 32:263–270. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Natarajan V, Gopalakrishnan R, Matta H,
Choi S, Gong S, Jeronimo A, Keerthipati PS, Morales A, Venkatesh H
and Chaudhary PM: A fast and sensitive luciferase-based assay for
antibody engineering and design of chimeric antigen receptors. Sci
Rep. 10:23182020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guo S and Xi X: Nanobody-enhanced chimeric
antigen receptor T-cell therapy: Overcoming barriers in solid
tumors with VHH and VNAR-based constructs. Biomark Res. 13:412025.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoo JW: Management of adverse events in
young adults and children with acute B-cell lymphoblastic leukemia
receiving anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
Blood Res. 58(S1): S20–S28. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qi Y, Liu H, Li X, Shi Y, Mu J, Li J, Wang
Y and Deng Q: Blinatumomab as salvage therapy in patients with
relapsed/refractory B-ALL who have failed/progressed after
anti-CD19-CAR T therapy. Ann Med. 55:22308882023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bouchkouj N, Kasamon YL, de Claro RA,
George B, Lin X, Lee S, Blumenthal GM, Bryan W, McKee AE and Pazdur
R: FDA approval summary: Axicabtagene ciloleucel for relapsed or
refractory large B-cell lymphoma. Clin Cancer Res. 25:1702–1708.
2019. View Article : Google Scholar
|
|
19
|
Fischer JW and Bhattarai N: CAR-T cell
therapy: Mechanism, management, and mitigation of inflammatory
toxicities. Front Immunol. 12:6930162021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miller JF: Immunological function of the
thymus. Lancet. 2:748–749. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miller JF: Analysis of the thymus
influence in leukaemogenesis. Nature. 191:248–249. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Taniguchi T, Matsui H, Fujita T, Takaoka
C, Kashima N, Yoshimoto R and Hamuro J: Structure and expression of
a cloned cDNA for human interleukin-2. Nature. 302:305–310. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Klaus SJ, Pinchuk LM, Ochs HD, Law CL,
Fanslow WC, Armitage RJ and Clark EA: Costimulation through CD28
enhances T cell-dependent B cell activation via CD40-CD40L
interaction. J Immunol. 152:5643–5652. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mousset CM, Hobo W, Woestenenk R, Preijers
F, Dolstra H and van der Waart AB: Comprehensive phenotyping of T
cells using flow cytometry. Cytometry A. 95:647–654. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Eshhar Z, Waks T, Gross G and Schindler
DG: Specific activation and targeting of cytotoxic lymphocytes
through chimeric single chains consisting of antibody-binding
domains and the gamma or zeta subunits of the immunoglobulin and
T-cell receptors. Proc Natl Acad Sci USA. 90:720–724. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han D, Xu Z, Zhuang Y, Ye Z and Qian Q:
Current progress in CAR-T cell therapy for hematological
malignancies. J Cancer. 12:326–334. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hong M, Clubb JD and Chen YY: Engineering
CAR-T cells for next-generation cancer therapy. Cancer Cell.
38:473–488. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eshhar Z, Waks T and Gross G: The
emergence of T-bodies/CAR T cells. Cancer J. 20:123–126. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Finney HM, Akbar AN and Lawson AD:
Activation of resting human primary T cells with chimeric
receptors: Costimulation from CD28, inducible costimulator, CD134,
and CD137 in series with signals from the TCR zeta chain. J
Immunol. 172:104–113. 2004. View Article : Google Scholar
|
|
30
|
Imai C, Mihara K, Andreansky M, Nicholson
IC, Pui CH, Geiger TL and Campana D: Chimeric receptors with 4-1BB
signaling capacity provoke potent cytotoxicity against acute
lymphoblastic leukemia. Leukemia. 18:676–684. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van der Stegen SJ, Hamieh M and Sadelain
M: The pharmacology of second-generation chimeric antigen
receptors. Nat Rev Drug Discov. 14:499–509. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Milone MC, Fish JD, Carpenito C, Carroll
RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B,
Danet-Desnoyers G, et al: Chimeric receptors containing CD137
signal transduction domains mediate enhanced survival of T cells
and increased antileukemic efficacy in vivo. Mol Ther.
17:1453–1464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park JH, Rivière I, Gonen M, Wang X,
Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et
al: Long-term follow-up of CD19 CAR therapy in acute lymphoblastic
leukemia. N Engl J Med. 378:449–459. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Porter DL, Levine BL, Kalos M, Bagg A and
June CH: Chimeric antigen receptor-modified T cells in chronic
lymphoid leukemia. N Engl J Med. 365:725–733. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhong XS, Matsushita M, Plotkin J, Riviere
I and Sadelain M: Chimeric antigen receptors combining 4-1BB and
CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and
CD8+ T cell-mediated tumor eradication. Mol Ther. 18:413–420. 2010.
View Article : Google Scholar
|
|
36
|
Pulè MA, Straathof KC, Dotti G, Heslop HE,
Rooney CM and Brenner MK: A chimeric T cell antigen receptor that
augments cytokine release and supports clonal expansion of primary
human T cells. Mol Ther. 12:933–941. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
George P, Dasyam N, Giunti G, Mester B,
Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, et
al: Third-generation anti-CD19 chimeric antigen receptor T-cells
incorporating a TLR2 domain for relapsed or refractory B-cell
lymphoma: A phase I clinical trial protocol (ENABLE). BMJ Open.
10:e0346292020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schultz L: Chimeric antigen receptor T
cell therapy for pediatric B-ALL: Narrowing the gap between early
and long-term outcomes. Front Immunol. 11:19852020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ramos CA, Rouce R, Robertson CS, Reyna A,
Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, et al: In
vivo fate and activity of second-versus third-generation
CD19-Specific CAR-T cells in B cell non-hodgkin's lymphomas. Mol
Ther. 26:2727–2737. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pietrobon V, Todd LA, Goswami A, Stefanson
O, Yang Z and Marincola F: Improving CAR T-cell persistence. Int J
Mol Sci. 22:108282021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wagner J, Wickman E, DeRenzo C and
Gottschalk S: CAR T cell therapy for solid tumors: Bright future or
dark reality? Mol Ther. 28:2320–2339. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chin DS, Lim CSY, Nordin F, Arifin N and
Jun TG: Antibody-dependent cell-mediated cytotoxicity through
natural killer (NK) cells: Unlocking NK cells for future
immunotherapy. Curr Pharm Biotechnol. 23:552–578. 2022. View Article : Google Scholar
|
|
43
|
Yasuda K, Nakanishi K and Tsutsui H:
Interleukin-18 in health and disease. Int J Mol Sci. 20:6492019.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ruixin S, Yifan L, Chuanlong W, Min Z,
Hong L, Guoxiu D, Zhengyang L, Yansha S, Yiwei D, Jingwen S, et al:
Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival
of EGFRvIII-targeting CAR-T cells in breast cancer. Biochem
Pharmacol. 212:1155362023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang M, Wen B, Anton OM, Yao Z, Dubois S,
Ju W, Sato N, DiLillo DJ, Bamford RN, Ravetch JV and Waldmann TA:
IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by
NK cells and macrophages. Proc Natl Acad Sci USA.
115:E10915–E10924. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Etxebeste-Mitxeltorena M, Del Rincón-Loza
I and Martín-Antonio B: Tumor secretome to adoptive cellular
immunotherapy: Reduce me before I make you my partner. Front
Immunol. 12:7178502021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu Y, Zhang M, Ramos CA, Durett A, Liu E,
Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, et al: Closely
related T-memory stem cells correlate with in vivo expansion of
CAR. CD19-T cells and are preserved by IL-7 and IL-15. Blood.
123:3750–3759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang X, Lv X and Song Y: Short-term
culture with IL-2 is beneficial for potent memory chimeric antigen
receptor T cell production. Biochem Biophys Res Commun.
495:1833–1838. 2018. View Article : Google Scholar
|
|
49
|
Santomasso B, Bachier C, Westin J, Rezvani
K and Shpall EJ: The other side of CAR T-cell therapy: Cytokine
release syndrome, neurologic toxicity, and financial Burden. Am Soc
Clin Oncol Educ Book. 39:433–444. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Guercio M, Manni S, Boffa I, Caruso S, Di
Cecca S, Sinibaldi M, Abbaszadeh Z, Camera A, Ciccone R, Polito VA,
et al: Inclusion of the inducible caspase 9 suicide gene in CAR
construct increases safety of CAR.CD19 T cell therapy in B-cell
malignancies. Front Immunol. 12:7556392021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Diaconu I, Ballard B, Zhang M, Chen Y,
West J, Dotti G and Savoldo B: Inducible caspase-9 selectively
modulates the toxicities of CD19-specific chimeric antigen
receptor-modified T cells. Mol Ther. 25:580–592. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
No authors listed. FDA okays second CAR-T
for Kite. Nat Biotechnol. 38:10122020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Galli S, Melidis L, Flynn SM, Varshney D,
Simeone A, Spiegel J, Madden SK, Tannahill D and Balasubramanian S:
DNA G-quadruplex recognition in vitro and in live cells by a
structure-specific nanobody. J Am Chem Soc. 144:23096–23103. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Majzner RG and Mackall CL: Clinical
lessons learned from the first leg of the CAR T cell journey. Nat
Med. 25:1341–1355. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Strohl WR and Naso M: Bispecific T-cell
redirection versus chimeric antigen receptor (CAR)-T cells as
approaches to kill cancer cells. Antibodies (Basel).
8:2019.PubMed/NCBI
|
|
56
|
Fujiwara K, Masutani M, Tachibana M and
Okada N: Impact of scFv structure in chimeric antigen receptor on
receptor expression efficiency and antigen recognition properties.
Biochem Biophys Res Commun. 527:350–357. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shah NN and Fry TJ: Mechanisms of
resistance to CAR T cell therapy. Nat Rev Clin Oncol. 16:372–385.
2019.PubMed/NCBI
|
|
58
|
Gorovits B and Koren E: Immunogenicity of
chimeric antigen receptor T-cell therapeutics. BioDrugs.
33:275–284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wagner DL, Fritsche E, Pulsipher MA, Ahmed
N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, et
al: Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin
Oncol. 18:379–393. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Long AH, Haso WM, Shern JF, Wanhainen KM,
Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara
VR, et al: 4-1BB costimulation ameliorates T cell exhaustion
induced by tonic signaling of chimeric antigen receptors. Nat Med.
21:581–590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sotillo E, Barrett DM, Black KL, Bagashev
A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, et
al: Convergence of acquired mutations and alternative splicing of
CD19 enables resistance to CART-19 immunotherapy. Cancer Discov.
5:1282–1295. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu W, Zou H, Guo L, Zhou Z, Xie Y, Guo H,
Wei G, Zhang K, Yin H, Wei S and Chi J: Coordinating oncogenesis
and immune evasion: KPNA2, GOLM1, and TK1 as novel CAR T-cell
targets in lung adenocarcinoma. Eur J Med Res. 30:7652025.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yan K and Xiao Z: Enhancing the antitumor
activity of CD19/BCMA CAR-T cells in vitro with a PD1IL7R chimeric
switch receptor. Cell Immunol. 415-416:1050012025. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Miller BR, Demarest SJ, Lugovskoy A, Huang
F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS
and Glaser SM: Stability engineering of scFvs for the development
of bispecific and multivalent antibodies. Protein Eng Des Sel.
23:549–557. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Jensen MC and Riddell SR: Design and
implementation of adoptive therapy with chimeric antigen
receptor-modified T cells. Immunol Rev. 257:127–144. 2014.
View Article : Google Scholar :
|
|
66
|
Zhang K, Geddie ML, Kohli N, Kornaga T,
Kirpotin DB, Jiao Y, Rennard R, Drummond DC, Nielsen UB, Xu L and
Lugovskoy AA: Comprehensive optimization of a single-chain variable
domain antibody fragment as a targeting ligand for a cytotoxic
nanoparticle. MAbs. 7:42–52. 2015. View Article : Google Scholar :
|
|
67
|
Broussau S, Lytvyn V, Simoneau M,
Guilbault C, Leclerc M, Nazemi-Moghaddam N, Coulombe N, Elahi SM,
McComb S and Gilbert R: Packaging cells for lentiviral vectors
generated using the cumate and coumermycin gene induction systems
and nanowell single-cell cloning. Mol Ther Methods Clin Dev.
29:40–57. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Okuma A: Generation of CAR-T cells by
lentiviral transduction. Methods Mol Biol. 2312:3–14. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ajina A and Maher J: Strategies to address
chimeric antigen receptor tonic signaling. Mol Cancer Ther.
17:1795–1815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gil D and Schrum AG: Strategies to
stabilize compact folding and minimize aggregation of
antibody-based fragments. Adv Biosci Biotechnol. 4:73–84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Jayaraman J, Mellody MP, Hou AJ, Desai RP,
Fung AW, Pham AHT, Chen YY and Zhao W: CAR-T design: Elements and
their synergistic function. EBioMedicine. 58:1029312020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hamers-Casterman C, Atarhouch T,
Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N and
Hamers R: Naturally occurring antibodies devoid of light chains.
Nature. 363:446–448. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Muyldermans S: Nanobodies: Natural
single-domain antibodies. Annu Rev Biochem. 82:775–797. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Greenberg AS, Avila D, Hughes M, Hughes A,
McKinney EC and Flajnik MF: A new antigen receptor gene family that
undergoes rearrangement and extensive somatic diversification in
sharks. Nature. 374:168–173. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Misson Mindrebo L, Liu H, Ozorowski G,
Tran Q, Woehl J, Khalek I, Smith JM, Barman S, Zhao F, Keating C,
et al: Fully synthetic platform to rapidly generate tetravalent
bispecific nanobody-based immunoglobulins. Proc Natl Acad Sci USA.
120:e22166121202023. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kunz P, Ortale A, Mücke N, Zinner K and
Hoheisel JD: Nanobody stability engineering by employing the ΔTm
shift; a comparison with apparent rate constants of heat-induced
aggregation. Protein Eng Des Sel. 32:241–249. 2019.PubMed/NCBI
|
|
77
|
Debie P, Lafont C, Defrise M, Hansen I,
van Willigen DM, van Leeuwen FWB, Gijsbers R, D'Huyvetter M,
Devoogdt N, Lahoutte T, et al: Size and affinity kinetics of
nanobodies influence targeting and penetration of solid tumours. J
Control Release. 317:34–42. 2020. View Article : Google Scholar
|
|
78
|
Vincke C, Loris R, Saerens D,
Martinez-Rodriguez S, Muyldermans S and Conrath K: General strategy
to humanize a camelid single-domain antibody and identification of
a universal humanized nanobody scaffold. J Biol Chem.
284:3273–3284. 2009. View Article : Google Scholar
|
|
79
|
Rahbarizadeh F, Ahmadvand D and Moghimi
SM: CAR T-cell bioengineering: Single variable domain of heavy
chain antibody targeted CARs. Adv Drug Deliv Rev. 141:41–46. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Honegger A: Engineering Antibodies for
Stability and Efficient Folding. Handbook of Experimental
Pharmacology. Chernajovsky Y and Nissim A: 181. Springer; Berlin,
Heidelberg: pp. 47–68. 2008, View Article : Google Scholar
|
|
81
|
Jovčevska I and Muyldermans S: The
therapeutic potential of nanobodies. BioDrugs. 34:11–26. 2020.
View Article : Google Scholar
|
|
82
|
Chanier T and Chames P: Nanobody
engineering: Toward next generation immunotherapies and
immunoimaging of cancer. Antibodies (Basel). 8:132019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Malavasi F, Deaglio S, Funaro A, Ferrero
E, Horenstein AL, Ortolan E, Vaisitti T and Aydin S: Evolution and
function of the ADP ribosyl cyclase/CD38 gene family in physiology
and pathology. Physiol Rev. 88:841–886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lonial S, Weiss BM, Usmani SZ, Singhal S,
Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, et
al: Daratumumab monotherapy in patients with treatment-refractory
multiple myeloma (SIRIUS): An open-label, randomised, phase 2
trial. Lancet. 387:1551–1560. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
van de Donk N, Richardson PG and Malavasi
F: CD38 antibodies in multiple myeloma: Back to the future. Blood.
131:13–29. 2018. View Article : Google Scholar
|
|
86
|
Li T, Qi S, Unger M, Hou YN, Deng QW, Liu
J, Lam CMC, Wang XW, Xin D, Zhang P, et al: Immuno-targeting the
multi-functional CD38 using nanobody. Sci Rep. 6:270552016.
View Article : Google Scholar
|
|
87
|
An N, Hou YN, Zhang QX, Li T, Zhang QL,
Fang C, Chen H, Lee HC, Zhao YJ and Du X: Anti-multiple myeloma
activity of nanobody-based anti-CD38 chimeric antigen receptor T
cells. Mol Pharm. 15:4577–4588. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Schriewer L, Schütze K, Petry K, Hambach
J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K,
et al: Nanobody-based CD38-specific heavy chain antibodies induce
killing of multiple myeloma and other hematological malignancies.
Theranostics. 10:2645–2658. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hambach J, Riecken K, Cichutek S, Schütze
K, Albrecht B, Petry K, Röckendorf JL, Baum N, Kröger N, Hansen T,
et al: Targeting CD38-expressing multiple myeloma and burkitt
lymphoma cells in vitro with nanobody-based chimeric antigen
receptors (Nb-CARs). Cells. 9:3212020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tseng YH, Ho HL, Lai CR, Luo YH, Tseng YC,
Whang-Peng J, Lin YH, Chou TY and Chen YM: PD-L1 expression of
tumor cells, macrophages, and immune cells in non-small cell lung
cancer patients with malignant pleural effusion. J Thorac Oncol.
13:447–453. 2018. View Article : Google Scholar
|
|
91
|
Ingram JR, Dougan M, Rashidian M, Knoll M,
Keliher EJ, Garrett S, Garforth S, Blomberg OS, Espinosa C, Bhan A,
et al: PD-L1 is an activation-independent marker of brown
adipocytes. Nat Commun. 8:6472017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li D, English H, Hong J, Liang T, Merlino
G, Day CP and Ho M: A novel PD-L1-targeted shark V(NAR)
single-domain-based CAR-T cell strategy for treating breast cancer
and liver cancer. Mol Ther Oncolytics. 24:849–863. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
De Munter S, Van Parys A, Bral L, Ingels
J, Goetgeluk G, Bonte S, Pille M, Billiet L, Weening K, Verhee A,
et al: Rapid and effective generation of nanobody based CARs using
PCR and gibson assembly. Int J Mol Sci. 21:8832020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Liu Y, Ao K, Bao F, Cheng Y, Hao Y, Zhang
H, Fu S, Xu J and Wu Q: Development of a bispecific nanobody
targeting CD20 on B-cell lymphoma cells and CD3 on T cells.
Vaccines (Basel). 10:13352022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Banihashemi SR, Hosseini AZ, Rahbarizadeh
F and Ahmadvand D: Development of specific nanobodies (VHH) for
CD19 immuno-targeting of human B-lymphocytes. Iran J Basic Med Sci.
21:455–464. 2018.PubMed/NCBI
|
|
96
|
Wang H, Wang L, Li Y, Li G, Zhang X, Jiang
D, Zhang Y, Liu L, Chu Y and Xu G: Nanobody-armed T cells endow
CAR-T cells with cytotoxicity against lymphoma cells. Cancer Cell
Int. 21:4502021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Maude SL, Laetsch TW, Buechner J, Rives S,
Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers
GD, et al: Tisagenlecleucel in children and young adults with
B-cell lymphoblastic leukemia. N Engl J Med. 378:439–448. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Carpenter RO, Evbuomwan MO, Pittaluga S,
Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT and Kochenderfer JN:
B-cell maturation antigen is a promising target for adoptive T-cell
therapy of multiple myeloma. Clin Cancer Res. 19:2048–2060. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Han L, Zhou J, Zhou K, Zhu X, Zhao L, Fang
B, Yin Q, Wei X, Zhou H, Li L, et al: Safety and efficacy of CAR-T
cell targeting BCMA in patients with multiple myeloma coinfected
with chronic hepatitis B virus. J Immunother Cancer. 8:e0009272020.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin
D, Guo T, Kou H, Liu L, Tang L, et al: A bispecific CAR-T cell
therapy targeting BCMA and CD38 in relapsed or refractory multiple
myeloma. J Hematol Oncol. 14:1612021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wei L, Xiao X, Jing X, Zheng Y, Sun X, Bai
W, Li M, Luo M and Xiao Y: Case report: Summary of multiple CAR-T
expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for
multiple myeloma. Front Immunol. 16:16077782025. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Slaney CY, Kershaw MH and Darcy PK:
Trafficking of T cells into tumors. Cancer Res. 74:7168–7174. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wu X, Giobbie-Hurder A, Liao X, Lawrence
D, McDermott D, Zhou J, Rodig S and Hodi FS: VEGF neutralization
plus CTLA-4 blockade alters soluble and cellular factors associated
with enhancing lymphocyte infiltration and humoral recognition in
melanoma. Cancer Immunol Res. 4:858–868. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chen DS and Hurwitz H: Combinations of
bevacizumab with cancer immunotherapy. Cancer J. 24:193–204. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Chinnasamy D, Yu Z, Theoret MR, Zhao Y,
Shrimali RK, Morgan RA, Feldman SA, Restifo NP and Rosenberg SA:
Gene therapy using genetically modified lymphocytes targeting
VEGFR-2 inhibits the growth of vascularized syngenic tumors in
mice. J Clin Invest. 120:3953–3968. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Spratlin JL, Cohen RB, Eadens M, Gore L,
Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, et
al: Phase I pharmacologic and biologic study of ramucirumab
(IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody
targeting the vascular endothelial growth factor receptor-2. J Clin
Oncol. 28:780–787. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Fukumura D, Kloepper J, Amoozgar Z, Duda
DG and Jain RK: Enhancing cancer immunotherapy using
antiangiogenics: Opportunities and challenges. Nat Rev Clin Oncol.
15:325–340. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Ma L, Gu K, Zhang CH, Chen XT, Jiang Y,
Melcher K, Zhang J, Wang M and Xu HE: Generation and
characterization of a human nanobody against VEGFR-2. Acta
Pharmacol Sin. 37:857–864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Rydén L, Jirström K, Bendahl PO, Fernö M,
Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE and Landberg G:
Tumor-specific expression of vascular endothelial growth factor
receptor 2 but not vascular endothelial growth factor or human
epidermal growth factor receptor 2 is associated with impaired
response to adjuvant tamoxifen in premenopausal breast cancer. J
Clin Oncol. 23:4695–4704. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Hajari Taheri F, Hassani M, Sharifzadeh Z,
Behdani M, Arashkia A and Abolhassani M: T cell engineered with a
novel nanobody-based chimeric antigen receptor against VEGFR2 as a
candidate for tumor immunotherapy. IUBMB Life. 71:1259–1267. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Sharifzadeh Z, Rahbarizadeh F, Shokrgozar
MA, Ahmadvand D, Mahboudi F, Jamnani FR and Moghimi SM: Genetically
engineered T cells bearing chimeric nanoconstructed receptors
harboring TAG-72-specific camelid single domain antibodies as
targeting agents. Cancer Lett. 334:237–244. 2013. View Article : Google Scholar
|
|
112
|
Jamnani FR, Rahbarizadeh F, Shokrgozar MA,
Mahboudi F, Ahmadvand D, Sharifzadeh Z, Parhamifar L and Moghimi
SM: T cells expressing VHH-directed oligoclonal chimeric HER2
antigen receptors: towards tumor-directed oligoclonal T cell
therapy. Biochim Biophys Acta. 1840:378–386. 2014. View Article : Google Scholar
|
|
113
|
Vitti Gambim V, Laufer-Amorim R, Fonseca
Alves RH, Grieco V and Fonseca-Alves CE: A comparative
meta-analysis and in silico analysis of differentially expressed
genes and proteins in canine and human bladder cancer. Front Vet
Sci. 7:5589782020. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sharifi J, Khirehgesh MR, Safari F and
Akbari B: EGFR and anti-EGFR nanobodies: Review and update. J Drug
Target. 29:387–402. 2021. View Article : Google Scholar
|
|
115
|
McComb S, Nguyen T, Shepherd A, Henry KA,
Bloemberg D, Marcil A, Maclean S, Zafer A, Gilbert R, Gadoury C, et
al: Programmable attenuation of antigenic sensitivity for a
nanobody-based EGFR chimeric antigen receptor through hinge domain
truncation. Front Immunol. 13:8648682022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Hosking MP, Shirinbak S, Omilusik K,
Chandra S, Kaneko MK, Gentile A, Yamamoto S, Shrestha B, Grant J,
Boyett M, et al: Preferential tumor targeting of HER2 by
iPSC-derived CAR T cells engineered to overcome multiple barriers
to solid tumor efficacy. Cell Stem Cell. 32:1087–1101.e4. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Bakhtiari SH, Rahbarizadeh F, Hasannia S,
Ahmadvand D, Iri-Sofla FJ and Rasaee MJ: Anti-MUC1 nanobody can
redirect T-body cytotoxic effector function. Hybridoma (Larchmt).
28:85–92. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
You F, Jiang L, Zhang B, Lu Q, Zhou Q,
Liao X, Wu H, Du K, Zhu Y, Meng H, et al: Phase 1 clinical trial
demonstrated that MUC1 positive metastatic seminal vesicle cancer
can be effectively eradicated by modified Anti-MUC1 chimeric
antigen receptor transduced T cells. Sci China Life Sci.
59:386–397. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Supimon K, Sangsuwannukul T, Sujjitjoon J,
Chieochansin T, Junking M and Yenchitsomanus PT: Cytotoxic activity
of anti-mucin 1 chimeric antigen receptor T cells expressing
PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Cytotherapy. 25:148–161. 2023. View Article : Google Scholar
|
|
120
|
Ishikawa Y, Tanaka N, Murakami K, Uchiyama
T, Kumaki S, Tsuchiya S, Kugoh H, Oshimura M, Calos MP and Sugamura
K: Phage phiC31 integrase-mediated genomic integration of the
common cytokine receptor gamma chain in human T-cell lines. J Gene
Med. 8:646–653. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Rath P, Kramer P, Biggs D, Preece C,
Hortin N, Diaz R, Perez-Alcantara M, Li X, Bolard A, Beer N, et al:
Optimizing approaches for targeted integration of transgenic
cassettes by integrase-mediated cassette exchange in mouse and
human stem cells. Stem Cells. 43:sxae0922025. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Li M, Choo B, Wong ZM, Filmus J and Buick
RN: Expression of OCI-5/glypican 3 during intestinal morphogenesis:
Regulation by cell shape in intestinal epithelial cells. Exp Cell
Res. 235:3–12. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Arbabi-Ghahroudi M, Tanha J and MacKenzie
R: Isolation of monoclonal antibody fragments from phage display
libraries. Methods Mol Biol. 502:341–364. 2009. View Article : Google Scholar
|
|
124
|
Zhou L, Li Y, Zheng D, Zheng Y, Cui Y, Qin
L, Tang Z, Peng D, Wu Q, Long Y, et al: Bispecific CAR-T cells
targeting FAP and GPC3 have the potential to treat hepatocellular
carcinoma. Mol Ther Oncol. 32:2008172024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Li N, Fu H, Hewitt SM, Dimitrov DS and Ho
M: Therapeutically targeting glypican-2 via single-domain
antibody-based chimeric antigen receptors and immunotoxins in
neuroblastoma. Proc Natl Acad Sci USA. 114:E6623–E6631.
2017.PubMed/NCBI
|
|
126
|
Astrof S, Crowley D, George EL, Fukuda T,
Sekiguchi K, Hanahan D and Hynes RO: Direct test of potential roles
of EIIIA and EIIIB alternatively spliced segments of fibronectin in
physiological and tumor angiogenesis. Mol Cell Biol. 24:8662–8670.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Efthymiou G, Saint A, Ruff M, Rekad Z,
Ciais D and Van Obberghen-Schilling E: Shaping Up the tumor
microenvironment with cellular fibronectin. Front Oncol.
10:6412020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Ma W, Wang Y, Zhang R, Yang F, Zhang D,
Huang M, Zhang L, Dorsey JF, Binder ZA, O'Rourke DM, et al:
Targeting PAK4 to reprogram the vascular microenvironment and
improve CAR-T immunotherapy for glioblastoma. Nat Cancer. 2:83–97.
2021. View Article : Google Scholar
|
|
129
|
Lutz EA, Jailkhani N, Momin N, Huang Y,
Sheen A, Kang BH, Wittrup KD and Hynes RO: Intratumoral
nanobody-IL-2 fusions that bind the tumor extracellular matrix
suppress solid tumor growth in mice. PNAS Nexus. 1:pgac2442022.
View Article : Google Scholar
|
|
130
|
Xie YJ, Dougan M, Jailkhani N, Ingram J,
Fang T, Kummer L, Momin N, Pishesha N, Rickelt S, Hynes RO and
Ploegh H: Nanobody-based CAR T cells that target the tumor
microenvironment inhibit the growth of solid tumors in
immunocompetent mice. Proc Natl Acad Sci USA. 116:7624–7631. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Alon-Zchut G, Zalk R, Huynh TT, Zalutsky
MR, Weizmann Y, Zarivach R and Papo N: Structural analysis of
nanobody interactions with their prostate-specific membrane antigen
binding epitopes. Int J Biol Macromol. 320(Pt 1): 1456932025.
View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Chatalic KL, Veldhoven-Zweistra J,
Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M and van
Weerden WM: A novel 111in-labeled anti-prostate-specific
membrane antigen nanobody for targeted SPECT/CT imaging of prostate
cancer. J Nucl Med. 56:1094–1099. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Georgiev T, Principi L, Galbiati A,
Gilardoni E, Neri D and Cazzamalli S: Targeted interleukin-2
enhances the in vivo anti-cancer activity of Pluvicto™. Eur J Nucl
Med Mol Imaging. 51:2332–2337. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Hassani M, Hajari Taheri F, Sharifzadeh Z,
Arashkia A, Hadjati J, van Weerden WM, Abdoli S, Modarressi MH and
Abolhassani M: Engineered jurkat cells for targeting
prostate-specific membrane antigen on prostate cancer cells by
nanobody-based chimeric antigen receptor. Iran Biomed J. 24:81–88.
2020. View Article : Google Scholar :
|
|
135
|
Ullah K, Addai Peprah F, Yu F and Shi H:
The application of prostate specific membrane antigen in CART-cell
therapy for treatment of prostate carcinoma (Review). Oncol Rep.
40:3136–3143. 2018.PubMed/NCBI
|
|
136
|
Khaleghi S, Rahbarizadeh F, Ahmadvand D,
Rasaee MJ and Pognonec P: A caspase 8-based suicide switch induces
apoptosis in nanobody-directed chimeric receptor expressing T
cells. Int J Hematol. 95:434–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Liu C, Wang Q, Li L, Gao F, Zhang Y and
Zhu Y: The peptide-based bispecific CAR T cells target EGFR and
tumor stroma for effective cancer therapy. Int J Pharm.
663:1245582024. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
De Munter S, Ingels J, Goetgeluk G, Bonte
S, Pille M, Weening K, Kerre T, Abken H and Vandekerckhove B:
Nanobody based dual specific CARs. Int J Mol Sci. 19:4032018.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Xia B, Lin K, Wang X, Chen F, Zhou M, Li
Y, Lin Y, Qiao Y, Li R, Zhang W, et al: Nanobody-derived bispecific
CAR-T cell therapy enhances the anti-tumor efficacy of T cell
lymphoma treatment. Mol Ther Oncolytics. 30:86–102. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu
YF, Xu J, Zhuang Y, Zhang W, Weng XQ, et al: Exploratory trial of a
biepitopic CAR T-targeting B cell maturation antigen in
relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA.
116:9543–9551. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Meeus F, Funeh CN, Awad RM, Zeven K,
Autaers D, De Becker A, Van Riet I, Goyvaerts C, Tuyaerts S, Neyns
B, et al: Preclinical evaluation of antigen-sensitive
B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions
for on-target, off-tumor toxicity. J Immunother Cancer.
12:e0091102024. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Wang H, Arulraj T, Anbari S and Popel AS:
Quantitative systems pharmacology modeling of macrophage-targeted
therapy combined with PD-L1 inhibition in advanced NSCLC. Clin
Transl Sci. 17:e138112024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Xie YJ, Dougan M, Ingram JR, Pishesha N,
Fang T, Momin N and Ploegh HL: Improved antitumor efficacy of
chimeric antigen receptor T cells that secrete single-domain
antibody fragments. Cancer Immunol Res. 8:518–529. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Lebrec H, Maier CC, Maki K, Ponce R,
Shenton J and Green S: Nonclinical safety assessment of engineered
T cell therapies. Regul Toxicol Pharmacol. 127:1050642021.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Kegler A, Koristka S, Bergmann R, Berndt
N, Arndt C, Feldmann A, Hoffmann A, Bornhäuser M, Schmitz M and
Bachmann MP: T cells engrafted with a UniCAR 28/z outperform UniCAR
BB/z-transduced T cells in the face of regulatory T cell-mediated
immunosuppression. Oncoimmunology. 8:e16216762019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Albert S, Arndt C, Feldmann A, Bergmann R,
Bachmann D, Koristka S, Ludwig F, Ziller-Walter P, Kegler A,
Gärtner S, et al: A novel nanobody-based target module for
retargeting of T lymphocytes to EGFR-expressing cancer cells via
the modular UniCAR platform. Oncoimmunology. 6:e12872462017.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Albert S, Arndt C, Koristka S, Berndt N,
Bergmann R, Feldmann A, Schmitz M, Pietzsch J, Steinbach J and
Bachmann M: From mono- to bivalent: Improving theranostic
properties of target modules for redirection of UniCAR T cells
against EGFR-expressing tumor cells in vitro and in vivo.
Oncotarget. 9:25597–25616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Berdeja JG, Madduri D, Usmani SZ,
Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M,
Lesokhin A, et al: Ciltacabtagene autoleucel, a B-cell maturation
antigen-directed chimeric antigen receptor T-cell therapy in
patients with relapsed or refractory multiple myeloma
(CARTITUDE-1): A phase 1b/2 open-label study. Lancet. 398:314–324.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Munshi NC, Anderson LD Jr, Shah N, Madduri
D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al:
Idecabtagene vicleucel in relapsed and refractory multiple myeloma.
N Engl J Med. 384:705–716. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Raje N, Berdeja J, Lin Y, Siegel D,
Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A,
et al: Anti-BCMA CAR T-Cell Therapy bb2121 in relapsed or
refractory multiple myeloma. N Engl J Med. 380:1726–1737. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Zhao WH, Liu J, Wang BY, Chen YX, Cao XM,
Yang Y, Zhang YL, Wang FX, Zhang PY, Lei B, et al: A phase 1,
open-label study of LCAR-B38M, a chimeric antigen receptor T cell
therapy directed against B cell maturation antigen, in patients
with relapsed or refractory multiple myeloma. J Hematol Oncol.
11:1412018. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J,
Liu J, Jin SW, Chen YX, Cao XM, Yang Y, et al: Four-year follow-up
of LCAR-B38M in relapsed or refractory multiple myeloma: A phase 1,
single-arm, open-label, multicenter study in China (LEGEND-2). J
Hematol Oncol. 15:862022. View Article : Google Scholar
|
|
153
|
Kamdar M, Solomon SR, Arnason J, Johnston
PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P,
Hernandez-Ilizaliturri F, et al: Lisocabtagene maraleucel versus
standard of care with salvage chemotherapy followed by autologous
stem cell transplantation as second-line treatment in patients with
relapsed or refractory large B-cell lymphoma (TRANSFORM): Results
from an interim analysis of an open-label, randomised, phase 3
trial. Lancet. 399:2294–2308. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Locke FL, Miklos DB, Jacobson CA, Perales
MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J,
Pagel JM, et al: Axicabtagene ciloleucel as second-line therapy for
large B-cell lymphoma. N Engl J Med. 386:640–654. 2022. View Article : Google Scholar
|
|
155
|
Gazeau N, Liang EC, Wu QV, Voutsinas JM,
Barba P, Iacoboni G, Kwon M, Ortega JLR, López-Corral L, Hernani R,
et al: Anakinra for refractory cytokine release syndrome or immune
effector cell-associated neurotoxicity syndrome after chimeric
antigen receptor T cell therapy. Transplant Cell Ther. 29:430–437.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Sborov DW, Pawlyn C, Ishida T, Huang JSY,
Benjamin R, Iida S, Popat R, Kuroda J, Pianko MJ, Ramakrishnan A,
et al: Evaluation of cytokine release syndrome (CRS) in patients
with relapsed or refractory multiple myeloma (RRMM) receiving
step-up priming doses and longer dosing intervals of elranatamab:
MagnetisMM-9. J Clin Oncol. 42:75222024. View Article : Google Scholar
|
|
157
|
Martin T, Usmani SZ, Berdeja JG, Agha M,
Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, et al:
Ciltacabtagene autoleucel, an anti-B-cell maturation antigen
chimeric antigen receptor T-cell therapy, for relapsed/refractory
multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol.
41:1265–1274. 2023. View Article : Google Scholar
|
|
158
|
Han L, Gao Q, Zhou K, Zhou J, Yin Q, Fang
B, Zhu XH, Zhang J, Bao C and Song Y: The clinical study of
anti-BCMA CAR-T with single-domain antibody as antigen binding
domain. J Clin Oncol. 39:80252021. View Article : Google Scholar
|
|
159
|
Wu A, Zhang T, Yu H, Cao Y, Zhang R, Shao
R, Liu B, Chen L, Xu K, Chen W, et al: Mechanisms underlying
resistance to CAR-T cell therapy and strategies for enhancement.
Cytokine Growth Factor Rev. 83:66–76. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Kearl TJ, Furqan F and Shah NN: CAR T-cell
therapy for B-cell lymphomas: Outcomes and resistance mechanisms.
Cancer Metastasis Rev. 44:122024. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Safarzadeh Kozani P, Safarzadeh Kozani P
and Rahbarizadeh F: Humanization of the antigen-recognition domain
does not impinge on the antigen-binding, cytokine secretion, and
antitumor reactivity of humanized nanobody-based CD19-redirected
CAR-T cells. J Transl Med. 22:6792024. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Nasiri F, Safarzadeh Kozani P and
Rahbarizadeh F: T-cells engineered with a novel VHH-based chimeric
antigen receptor against CD19 exhibit comparable tumoricidal
efficacy to their FMC63-based counterparts. Front Immunol.
14:10638382023. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Krol VE, Bansal A, Kethamreddy M,
Ellinghuysen JR, Vail DJ, Lucien-Matteoni F, Dong H, Park SS and
Pandey MK: Synthesis and in vitro evaluation of a scandium-44
radiolabeled nanobody as a PD-L1 PET imaging probe. Pharmaceutics.
17:7962025. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Bolzati C and Spolaore B: Enzymatic
methods for the site-specific radiolabeling of targeting proteins.
Molecules. 26:34922021. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Hanke L, Sheward DJ, Pankow A, Vidakovics
LP, Karl V, Kim C, Urgard E, Smith NL, Astorga-Wells J, Ekström S,
et al: Multivariate mining of an alpaca immune repertoire
identifies potent cross-neutralizing SARS-CoV-2 nanobodies. Sci
Adv. 8:eabm02202022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Takeuchi T, Kawanishi M, Nakanishi M,
Yamasaki H and Tanaka Y: Phase II/III results of a trial of
anti-tumor necrosis factor multivalent NANOBODY compound
ozoralizumab in patients with rheumatoid arthritis. Arthritis
Rheumatol. 74:1776–1785. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Yuen D, Feeney OM, Noi L, Shengule S,
McLeod VM, Reitano P, Tsegay S, Hufton R, Houston ZH, Fletcher NL,
et al: Nanobody-mediated cellular uptake maximizes the potency of
polylysine dendrimers while preserving solid tumor penetration. ACS
Nano. 19:6044–6057. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Olkowski CP, Basuli F, Fernandes B, Ghaemi
B, Shi J, Zhang HH, Farber JM, Escorcia FE, Choyke PL and Jacobson
O: Comparative kidney uptake of nanobody-based PET tracers labeled
with various fluorine-18-labeled prosthetic groups. Mol Pharm.
22:533–543. 2025. View Article : Google Scholar
|
|
169
|
Chen Y, Xiong T, Peng Q, Du J, Sun W, Fan
J and Peng X: Self-reporting photodynamic nanobody conjugate for
precise and sustainable large-volume tumor treatment. Nat Commun.
15:69352024. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Heremans J, Maximilian Awad R, Bridoux J,
Ertveldt T, Caveliers V, Madder A, Hoogenboom R, Devoogdt N, Ballet
S, Hernot S, et al: Sustained release of a human PD-L1
single-domain antibody using peptide-based hydrogels. Eur J Pharm
Biopharm. 196:1141832024. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Schubert ML, Schmitt A, Hückelhoven-Krauss
A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S,
Jopp-Saile L, Wang L, et al: Treatment of adult ALL patients with
third-generation CD19-directed CAR T cells: Results of a pivotal
trial. J Hematol Oncol. 16:792023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Ren Q, Zu Y, Su H, Lu Q, Xiang B, Luo Y,
Zhang J and Song Y: Single VHH-directed BCMA CAR-NK cells for
multiple myeloma. Exp Hematol Oncol. 12:982023. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Sadeghi A, Behdani M, Muyldermans S,
Habibi-Anbouhi M and Kazemi-Lomedasht F: Development of a
mono-specific anti-VEGF bivalent nanobody with extended plasma
half-life for treatment of pathologic neovascularization. Drug Test
Anal. 12:92–100. 2020. View Article : Google Scholar
|
|
174
|
Budi HS, Ahmad FN, Achmad H, Ansari MJ,
Mikhailova MV, Suksatan W, Chupradit S, Shomali N and Marofi F:
Human epidermal growth factor receptor 2 (HER2)-specific chimeric
antigen receptor (CAR) for tumor immunotherapy; recent progress.
Stem Cell Res Ther. 13:402022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Li H, Zhong D, Luo H, Shi W, Xie S, Qiang
H, Zhu L, Gao L, Liu J, Sun S, et al: Nanobody-based CAR T cells
targeting intracellular tumor antigens. Biomed Pharmacother.
156:1139192022. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Heitzeneder S, Bosse KR, Zhu Z, Zhelev D,
Majzner RG, Radosevich MT, Dhingra S, Sotillo E, Buongervino S,
Pascual-Pasto G, et al: GPC2-CAR T cells tuned for low antigen
density mediate potent activity against neuroblastoma without
toxicity. Cancer Cell. 40:53–69.e9. 2022. View Article : Google Scholar :
|
|
177
|
Mailankody S, Jakubowiak AJ, Htut M, Costa
LJ, Lee K, Ganguly S, Kaufman JL, Siegel DSD, Bensinger W, Cota M,
et al: Orvacabtagene autoleucel (orva-cel), a B-cell maturation
antigen (BCMA)-directed CAR T cell therapy for patients (pts) with
relapsed/refractory multiple myeloma (RRMM): Update of the phase
1/2 EVOLVE study (NCT03430011). J Clin Oncol. 38:85042020.
View Article : Google Scholar
|
